Funded Biomarker Testing
52 items
1p/19q, CDKN2A testing should be performed on patients who test positive for an IDH1 mutation.
Funded Biomarker Disease Site: Central Nervous System (CNS)
Biomarker: 1p/19q, CDKN2A
Testing Method:Single Nucleotide Polymorphism (SNP)
Testing Site: London Health Sciences Centre, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, Unity Health - St. Michael's Hospital, University Health Network
BRAF testing should be performed for colorectal cancer cases with abnormal MLH1 results.
Funded Biomarker Disease Site: Colorectal
Biomarker: BRAF
Testing Method:Panel
Testing Site: Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, Mount Sinai Hospital, The Ottawa Hospital, Trillium Health Partners, University Health Network
Cytogenetic analysis (karyotyping) for all new diagnoses of MDS, MPN, or MDS/MPN in line with established criteria.
Funded Biomarker Disease Site: Hematology
Biomarker: TBC
Testing Method:Cytogenetics (Karyotyping)
Testing Site: Children's Hospital of Eastern Ontario (CHEO), Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, North York General Hospital, St. Joseph's Healthcare Hamilton, Trillium Health Partners, University Health Network
Evaluation of genomic biomarkers in cases of MDS, MPN, or MDS/MPN for diagnostic sub-classification, prognosis or therapeutic guidance.
Funded Biomarker Disease Site: Hematology
Biomarker: TBC
Testing Method:Panel
Testing Site: Children's Hospital of Eastern Ontario (CHEO), Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, University Health Network
FISH analysis in cases of MDS, MPN, MDS/MPN where karyotyping is insufficient or criteria for additional testing is met.
Funded Biomarker Disease Site: Hematology
Biomarker: TBC
Testing Method:Fluoroscence In Situ Hybridization (FISH)
Testing Site: Children's Hospital of Eastern Ontario (CHEO), Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, North York General Hospital, St. Joseph's Healthcare Hamilton, Trillium Health Partners, University Health Network
For IDH Wild-Type patients diagnosed with Grade II and III tumours, sequencing should be performed.
Funded Biomarker Disease Site: Central Nervous System (CNS)
Biomarker: +7/-10
Testing Method:Single Nucleotide Polymorphism (SNP)
Testing Site: London Health Sciences Centre, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, Unity Health - St. Michael's Hospital, University Health Network
For IDH wild-type patients diagnosed with Grade II and III tumours, sequencing should be performed.
Funded Biomarker Disease Site:
Biomarker: EGFR, IDH, TERT
Testing Method:Sequencing
Testing Site: London Health Sciences Centre, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, Unity Health - St. Michael's Hospital, University Health Network
H3-K27M testing should be performed on patients diagnosed with a glioma tumour in the midline location.
Funded Biomarker Disease Site: Central Nervous System (CNS)
Biomarker: H3-K27M
Testing Method:Immunohistochemistry (IHC)
Testing Site: London Health Sciences Centre, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, Unity Health - St. Michael's Hospital, University Health Network
MGMT testing should be performed on all Grade IV patients > 55, all Grade III patients >55 and IDH wild-type Grade III patients ≤ 55.
Funded Biomarker Disease Site: Central Nervous System (CNS)
Biomarker: MGMT Methylation
Testing Method:Methylation
Testing Site: London Health Sciences Centre, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, Unity Health - St. Michael's Hospital, University Health Network
Promoter Methylation testing should be performed for all MMR cases with abnormal MLH1 results*.
Funded Biomarker Disease Site: Adrenal Gland, Bladder/ Urothelial, Colorectal, Endometrium, Esophagus, Hepatobiliary, Ocular, Ovary, Pancreas, Skin, Small Bowel, Stomach
Biomarker: MLH1 Methylation
Testing Method:Methylation
Testing Site: Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, Mount Sinai Hospital, Trillium Health Partners, University Health Network
Reflex testing for all newly diagnosed paragangliomas (to inform need for germline testing)
Funded Biomarker Disease Site: Multiple Disease Sites
Biomarker: SDHB
Testing Method:Immunohistochemistry (IHC)
Testing Site: London Health Sciences Centre, Mount Sinai Hospital, Sunnybrook Health Sciences Centre, University Health Network, William Osler Health System
Reflex testing for the diagnosis of serous tumours (epithelial ovarian, fallopian tube, peritoneal cancers) when needed to establish histologic subtype.
Funded Biomarker Disease Site: Ovary
Biomarker: p53, WT1
Testing Method:Immunohistochemistry (IHC)
Testing Site: Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, Markham Stouffville Hospital (Oak Valley Health), Mount Sinai Hospital, North Bay Regional Health Centre, North York General Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, Unity Health - St. Michael's Hospital, University Health Network, William Osler Health System